Ramez Kouzy, MD

Peer-Reviewed Articles

1. El Kouzi Z, Mohammed MA, Rooney MK, Kouzy R, Chen JJ, Shah S, Al Bitar T, Gadoue SM, Hassanzadeh C, Frank S, Tran PT, Tang C, Choi S, Park RJ, Hoffman K, McGuire SE, Mok H, Nguyen QN, Samman AB, Rahman Z, Shelan M, Eid T, Mohamad O. Association between author specialty and reported outcomes in nonrandomized comparisons of prostatectomy versus radiation. JNCI Cancer Spectr, 2026. e-Pub 2026. PMID: 42390011.
2. Abi Jaoude J, Lau A, Yuan Y, Meimoun NS, De B, Liao K, Kouzy R, Nieves-Jimenez HR, Poenisch F, Balter PA, Brock KK, Sawakuchi GO, Vauthey JN, Tzeng CD, Shamsutdinova D, Lazar AJ, Chatterjee D, Holliday EB, Smith GL, Minsky BD, Das P, Koong AC, Lee SS, Tran Cao HS, Javle M, Kwong L, Koay EJ, Ludmir EB. Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy. Clin Cancer Res 32(10):2079-2087, 2026. e-Pub 2026. PMID: 41923341.
3. Fis-Loperena M, Kouzy R, Thomas RJ, Cha EE, Manzar GS, Paulino AC, Yoder AK. Radiation Therapy Documentation Deficiencies in Cancer Survivorship Documents. Pract Radiat Oncol, 2026. e-Pub 2026. PMID: 42092691.
4. Sherry AD, Msaouel P, Kupferman GS, Lin TA, Abi Jaoude J, Kouzy R, El-Alam MB, Patel R, Koong A, Lin C, Passy AH, Miller AM, Beck EJ, Fuller CD, Meirson T, McCaw ZR, Ludmir EB. Interpreting Treatment Effects Using Posterior Probabilities: A Bayesian Reanalysis of 230 Phase III Oncology Trials. JCO Clin Cancer Inform 10(2):e2500303, 2026. e-Pub 2026. PMID: 42066235.
5. Schadler K, Klopp A, Kouzy R, Krishnamani PP, Filson R, Moody A, Grubbs E, Munoz N, Payne L, Stapleton S, Chung C. Knowledge and Use of Artificial Intelligence Among Oncology Faculty and Trainees at a Comprehensive Cancer Center in 2025. JCO Clin Cancer Inform 10(2):e2500300, 2026. e-Pub 2026. PMID: 42202236.
6. Kouzy R, Ibrahim I, Nemr P, Vinjamuri S, Ballout B, Diaz JSGG, Figueroa DN, Alam MBE, Kouzi ZE, Hassanzadeh C, Mohamad O, Weil C, Colbert L, Klopp A. Evaluation of AI chatbot responses to brachytherapy frequently asked questions. Brachytherapy 25(2):275-282, 2026. e-Pub 2026. PMID: 41407567.
7. Hsu EJ, Sherry AD, Lin TA, Abi Jaoude J, Kouzy R, Mccaw Z, Meirson T, Msaouel P, Ludmir EB. Differential censoring in overall survival in phase 3 oncology clinical trials. J Natl Cancer Inst, 2025. e-Pub 2025. PMID: 41455090.
8. Kouzy R, Rooney MK, Cha EE, Vinjamuri S, Wu H, Kouzi ZE, Mohamad O, Sims TT, Weil CR, Taku N, Lin LL, Jhingran A, Eifel P, Joyner M, Colbert LE, Klopp AH. AI based sentiment analysis of online discussions related to cervical brachytherapy. Tech Innov Patient Support Radiat Oncol 36:100340, 2025. e-Pub 2025. PMID: 41473390.
9. Grippin AJ, Marconi C, Copling S, Li N, Braun C, Woody C, Young E, Gupta P, Wang M, Wu A, Jeong SD, Soni D, Weidert F, Xie C, Goldenberg E, Kim A, Zhao C, DeVries A, Castillo P, Lohray R, Rooney MK, Schrank BR, Wang Y, Ma Y, Chang E, Kouzy R, Dyson K, Jafarnia J, Nariman N, Gladish G, New J, Argueta A, Amaya D, Thomas N, Doty A, Chen J, Copling N, Alatrash G, Simon J, Davies AB, Dennis W, Liang R, Lewis J, Wei X, Rinsurongkawong W, Vaporciyan AA, Johns A, Lee J, Lee JH, Sun R, Sharma P, Tran H, Zhang J, Gibbons DL, Wargo J, Kim BYS, Heymach JV, Mendez-Gomez HR, Jiang W, Sayour EJ, Lin SH. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature 647(8089):488-497, 2025. e-Pub 2025. PMID: 41125896.
10. Sherry AD, Msaouel P, Miller AM, Lin TA, Kupferman GS, Abi Jaoude J, Kouzy R, El-Alam MB, Patel R, Koong A, Lin C, Meirson T, McCaw ZR, Ludmir EB. Bayesian interim analysis and efficiency of phase III randomized trials. Br J Cancer 133(8):1145-1151, 2025. e-Pub 2025. PMID: 40789942.
11. Rajan SS, Ning MS, Jacobson M, Simiele SJ, Bruno T, Kouzy R, Yoshida-Court K, Cisneros-Napravnik T, Yu H, Stafford J, Kim Y, Mathew G, Cordova RA, Domingo M, Jhingran A, Lin LL, Joyner M, Sims TT, Colbert L, Venkatesan AM, Klopp A. Iterative intraoperative 3T MRI (iMRI)-guided brachytherapy: A prospective study on enhancing implantation precision and dosimetric gains in advanced gynecologic cancers. Brachytherapy 24(6):844-853, 2025. e-Pub 2025. PMID: 40816920.
12. Sherry AD, Msaouel P, Miller AM, Lin TA, Abi Jaoude J, Kouzy R, Passy AH, Meirson T, Ignatiadis N, McCaw ZR, van Zwet E, Ludmir EB. Reproducibility of statistically significant phase III oncology trials: An In Silico meta-epidemiological analysis. Eur J Cancer 226:115596, 2025. e-Pub 2025. PMID: 40628175.
13. Noticewala SS, Grippin AJ, Kouzy R, Abi Jaoude J, Miller A, Sherry A, Ludmir EB. Effect size estimation in cooperative group- and industry-sponsored phase 3 oncology trials. J Natl Cancer Inst 117(8):1738-1742, 2025. e-Pub 2025. PMID: 40220316.
14. Sherry AD, Liu Y, Msaouel P, Lin TA, Koong A, Lin C, Abi Jaoude J, Patel RR, Kouzy R, El-Alam MB, Miller AM, Owiwi M, Ofer J, Bomze D, McCaw ZR, Meirson T, Ludmir EB. Survival-inferred fragility of statistical significance in phase III oncology trials. NPJ Precis Oncol 9(1):256, 2025. e-Pub 2025. PMID: 40707724.
15. Attar-Olyaee R, Kouzy R, Rooney MK, El-Kouzi Z, Hoffman KE, Gadoue SM, Hassanzadeh CJ, Li JJ, Mohamad O. Cancer Risk Concerns and Communication Gaps Regarding GLP-1 Medications. JAMA Netw Open 8(7):e2521878, 2025. e-Pub 2025. PMID: 40679829.
16. Miller AM, Passy AH, Sherry AD, Kouzy R, Abi Jaoude J, Lin TA, Kupferman GS, Beck EJ, Msaouel P, Ludmir EB. Incomplete Toxicity Reporting and Use of Toxicity-Minimizing Language in Phase III Oncology Trials. JCO Oncol Pract 21(7):979-988, 2025. e-Pub 2025. PMID: 39778122.
17. Kouzy R, Hong JC, Bitterman DS. One shot at trust: building credible evidence for medical artificial intelligence. Lancet Digit Health 7(7):100883, 2025. e-Pub 2025. PMID: 40752990.
18. Yun HS, Zhang KYC, Kouzy R, Marshall IJ, Li JJ, Wallace BC. Caught in the Web of Words: Do LLMs Fall for Spin in Medical Literature?. Proc Mach Learn Res 287:458-479, 2025. e-Pub 2025. PMID: 41257216.
19. Kleber TJ, Sherry AD, Arifin AJ, Kupferman GS, Kouzy R, Abi Jaoude J, Lin TA, Beck EJ, Miller AM, Passy AH, McCaw ZR, Msaouel P, Ludmir EB. Justification, margin values, and analysis populations for oncologic noninferiority and equivalence trials: a meta-epidemiological study. J Natl Cancer Inst 117(5):898-906, 2025. e-Pub 2025. PMID: 39657246.
20. Kouzy R, Kai M, Le-Petross HT, Saleem S, Woodward WA. Use of natural language processing to identify patients with inflammatory breast cancer across a health-care system. JNCI Cancer Spectr 9(3), 2025. e-Pub 2025. PMID: 40493814.
21. Sherry AD, Passy AH, Abi Jaoude J, Lin TA, Kouzy R, Msaouel P, Ludmir EB. Treatment group-specific inferences in Phase III Randomized Oncology Trials. Acta Oncol 64:470-474, 2025. e-Pub 2025. PMID: 40126209.
22. Mohamad O, Kouzi ZE, Kouzy R, Choi S, Mok H, Hoffman K, Nguyen QN, Hassanzadeh CJ, Tang C, Park RJ, Shah SJ, McGuire SE, Mayo LL, Kim Y, Prajapati S, Vijayan S, Kudchadker RJ, Bruno TL, Frank SJ. Safety and early outcomes of proton therapy and low-dose rate brachytherapy boost for patients with prostate cancer. Brachytherapy 24(2):301-309, 2025. e-Pub 2025. PMID: 40024668.
23. Sherry AD, Liu Y, Msaouel P, Lin TA, Koong A, Lin C, Jaoude JA, Patel RR, Kouzy R, El-Alam MB, Miller AM, Owiwi M, Ofer J, Bomze D, McCaw ZR, Meirson T, Ludmir EB. Survival-Inferred Fragility of Statistical Significance in Phase III Oncology Trials. medRxiv, 2025. e-Pub 2025. PMID: 39867397.
24. Sherry AD, Lin TA, McCaw ZR, Beck EJ, Kouzy R, Abi Jaoude J, Passy AH, Miller AM, Kupferman GS, Fuller CD, Thomas CR Jr, Koay EJ, Tang C, Msaouel P, Ludmir EB. Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase III oncology trials. Int J Cancer 155(11):1939-1943, 2024. e-Pub 2024. PMID: 39138841.
25. Sherry AD, Lin TA, McCaw ZR, Beck EJ, Kouzy R, Abi Jaoude J, Passy AH, Miller AM, Kupferman GS, Fuller CD, Thomas CR Jr, Koay EJ, Tang C, Msaouel P, Ludmir EB. Off-Protocol Radiation Therapy in Phase 3 Metastatic Solid Tumor Trials. Int J Radiat Oncol Biol Phys 120(5):1239-1244, 2024. e-Pub 2024. PMID: 39352322.
26. Florez MA, De B, Kowalchuk R, Tang C, Bishop AJ, Kouzy R, Amini B, Briere T, Beckham TH, Wang C, Li J, Tatsui CE, Rhines LD, Brown PD, Merrell K, Ghia AJ. Validation of the prognostic index for spine metastasis (PRISM) for stratifying survival in patients treated with spinal stereotactic body radiation. Radiother Oncol 201:110570, 2024. e-Pub 2024. PMID: 39362605.
27. Lin TA, McCaw ZR, Koong A, Lin C, Abi Jaoude J, Patel R, Kouzy R, El Alam MB, Sherry AD, Noticewala SS, Fuller CD, Thomas CR Jr, Sun R, Lee JJ, Lin R, Yuan Y, Shyr Y, Meirson T, Ludmir EB. Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation. Clin Cancer Res 30(20):4791-4799, 2024. e-Pub 2024. PMID: 39133081.
28. Sherry AD, Msaouel P, Kupferman GS, Lin TA, Abi Jaoude J, Kouzy R, McCaw ZR, Ludmir EB, van Zwet E. Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology. JCO Precis Oncol 8:e2400363, 2024. e-Pub 2024. PMID: 39348660.
29. Sherry AD, Passy AH, McCaw ZR, Abi Jaoude J, Lin TA, Kouzy R, Miller AM, Kupferman GS, Beck EJ, Msaouel P, Ludmir EB. Increasing Power in Phase III Oncology Trials With Multivariable Regression: An Empirical Assessment of 535 Primary End Point Analyses. JCO Clin Cancer Inform 8:e2400102, 2024. e-Pub 2024. PMID: 39213473.
30. Beck EJ, Sherry AD, Florez MA, Kouzy R, Abi Jaoude J, Lin TA, Miller AM, Passy AH, Kupferman GS, Patel RR, Chino F, Higbie VS, Parseghian CM, Overman MJ, Minsky BD, Thomas CR Jr, Tang C, Msaouel P, Ludmir EB. Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials. Cancer Res Commun 4(8):2183-2188, 2024. e-Pub 2024. PMID: 39099199.
31. Sherry AD, Msaouel P, Kupferman GS, Lin TA, Abi Jaoude J, Kouzy R, El-Alam MB, Patel R, Koong A, Lin C, Passy AH, Miller AM, Beck EJ, Fuller CD, Meirson T, McCaw ZR, Ludmir EB. Towards Treatment Effect Interpretability: A Bayesian Re-analysis of 194,129 Patient Outcomes Across 230 Oncology Trials. medRxiv, 2024. e-Pub 2024. PMID: 39108512.
32. Sherry AD, Msaouel P, Miller AM, Lin TA, Kupferman GS, Jaoude JA, Kouzy R, El-Alam MB, Patel R, Koong A, Lin C, Meirson T, McCaw ZR, Ludmir EB. Bayesian Interim Analysis and Efficiency of Phase III Randomized Trials. medRxiv, 2024. e-Pub 2024. PMID: 38978666.
33. Hsu EJ, Lin TA, Dabush DR, McCaw Z, Koong A, Lin C, Abi Jaoude J, Patel R, Kouzy R, El Alam MB, Noticewala S, Yang Y, Sherry AD, Fuller CD, Thomas CR Jr, Tang C, Msaouel P, Das P, Huang B, Tian L, Sun R, Lee JJ, Meirson T, Ludmir EB. Association of differential censoring with survival and suboptimal control arms among oncology clinical trials. J Natl Cancer Inst 116(6):990-994, 2024. e-Pub 2024. PMID: 38331394.
34. Kouzy R, El Alam MB, Corrigan KL, Lalani HS, Ludmir EB. Patient-Level Savings on Generic Drugs Through the Mark Cuban Cost Plus Drug Company. JAMA Health Forum 5(6):e241468, 2024. e-Pub 2024. PMID: 38874962.
35. Kim M, Maldonado JA, Pandey P, El Alam MB, Kouzy R, Christopherson K, Minsky BD, Nugyen QN, Grosshans D, Lin LL, Mitchell MP, Klopp AH, Lee PP, Bird J, Satcher R, Lewis VO, Lin PP, Tang C, Koong AC, Moon B, Colbert LE. Single-fraction radiation retreatment for bone metastases: role of a rapid access clinic. BMJ Support Palliat Care, 2024. e-Pub 2024. PMID: 38843933.
36. Shi C, De B, Tran Cao HS, Liu S, Florez MA, Kouzy R, Grippin AJ, Katz MHG, Tzeng CD, Ikoma N, Kim MP, Lee S, Willis J, Noticewala SS, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Ludmir EB, Koay EJ. Escalated-dose radiotherapy for unresected locally advanced pancreatic cancer: Patterns of care and survival in the United States. Cancer Med 13(12):e7434, 2024. e-Pub 2024. PMID: 38923407.
37. Ludmir EB, Hoffman KE, Jhingran A, Kouzy R, Ip MP, Sturdevant L, Ning MS, Minsky BD, McAleer MF, Chronowski GM, Arzu IY, Reed VK, Garg AK, Roberts T, Eastwick GA, Olson MR, Selek U, Gabel M, Koong AC, Kupferman ME, Kuban DA. Implementation and Efficacy of a Large-Scale Radiation Oncology Case-Based Peer-Review Quality Program across a Multinational Cancer Network. Pract Radiat Oncol 14(3):e173-e179, 2024. e-Pub 2024. PMID: 38176466.
38. Sherry AD, Hahn AW, McCaw ZR, Abi Jaoude J, Kouzy R, Lin TA, Minsky B, Fuller CD, Meirson T, Msaouel P, Ludmir EB. Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020. JAMA Netw Open 7(3):e243379, 2024. e-Pub 2024. PMID: 38546648.
39. Sherry AD, Msaouel P, Lin TA, Abi Jaoude J, Kouzy R, Beck EJ, Miller AM, Passy AH, Kupferman GS, Koay EJ, Fuller CD, Thomas CR, McCaw ZR, Ludmir EB. Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials. BMJ Oncol 3(1):e000322, 2024. e-Pub 2024. PMID: 39886131.
40. Sherry AD, Corrigan KL, Kouzy R, Jaoude JA, Yang Y, Patel RR, Totten DJ, Newman NB, Das P, Taniguchi C, Minsky B, Snyder RA, Fuller CD, Ludmir E. Prevalence, trends, and characteristics of trials investigating local therapy in contemporary phase 3 clinical cancer research. Cancer 129(21):3430-3438, 2023. e-Pub 2023. PMID: 37382235.
41. Sherry AD, Msaouel P, McCaw ZR, Abi Jaoude J, Hsu EJ, Kouzy R, Patel R, Yang Y, Lin TA, Taniguchi CM, Rodel C, Fokas E, Tang C, Fuller CD, Minsky B, Meirson T, Sun R, Ludmir EB. Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 Fallacy. Eur J Cancer 194:113357, 2023. e-Pub 2023. PMID: 37827064.
42. Florez MA, Jaoude JA, Patel RR, Kouzy R, Lin TA, De B, Beck EJ, Taniguchi CM, Minsky BD, Fuller CD, Lee JJ, Kupferman M, Raghav KP, Overman MJ, Thomas CR Jr, Ludmir EB. Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials. JAMA Netw Open 6(5):e2313819, 2023. e-Pub 2023. PMID: 37195664.
43. Corrigan KL, Reeve BB, Salsman JM, Siembida EJ, Andring LM, Geng Y, Kouzy R, Livingston JA, Peterson SK, Bishop AJ, Smith GL, Gunther JR, Parsons SK, Roth M. Health-related quality of life in adolescents and young adults with cancer who received radiation therapy: a scoping review. Support Care Cancer 31(4):230, 2023. e-Pub 2023. PMID: 36961516.
44. Elnaggar JH, Huynh VO, Lin D, Hillman RT, Abana CO, El Alam MB, Tomasic KC, Karpinets TV, Kouzy R, Phan JL, Wargo J, Holliday EB, Das P, Mezzari MP, Ajami NJ, Lynn EJ, Minsky BD, Morris VK, Milbourne A, Messick CA, Klopp AH, Futreal PA, Taniguchi CM, Schmeler KM, Colbert LE. HPV-related anal cancer is associated with changes in the anorectal microbiome during cancer development. Front Immunol 14:1051431, 2023. e-Pub 2023. PMID: 37063829.
45. Corrigan KL, Kouzy R, Jaoude JA, Patel RR, Layman RM, Giordano SH, Woodward WA, Smith BD, Shaitelman SF, Ludmir EB. Inclusion of premenopausal women in breast cancer clinical trials. Breast 66:204-207, 2022. e-Pub 2022. PMID: 36327626.
46. Lin D, El Alam MB, Jaoude JA, Kouzy R, Phan JL, Elnaggar JH, Resendiz B, Medrano AYD, Lynn EJ, Nguyen ND, Noticewala SS, Mathew GG, Holliday EB, Minsky BD, Das P, Morris VK, Eng C, Mezzari MP, Petrosino JF, Ajami NJ, Klopp AH, Taniguchi CM, Colbert LE. Microbiome Dynamics During Chemoradiation Therapy for Anal Cancer. Int J Radiat Oncol Biol Phys 113(5):974-984, 2022. e-Pub 2022. PMID: 35513187.
47. Kouzy R, Abi Jaoude J, Minsky BD, Das P, Koong AC, Subbiah IM, Ludmir EB, Taniguchi CM. Gastrointestinal malignancies and supportive care trials: a snapshot of the last two decades. BMJ Support Palliat Care 12(1):42-45, 2022. e-Pub 2022. PMID: 32943466.
48. Patel RR, Parisi R, Verma V, Kouzy R, Abi Jaoude J, Lin TA, Fuller CD, VanderWalde NA, Jagsi R, Smith BD, Guadagnolo BA, Thomas CR Jr, Ludmir EB. Association between Prior Malignancy Exclusion Criteria and Age Disparities in Cancer Clinical Trials. Cancers (Basel) 14(4), 2022. e-Pub 2022. PMID: 35205795.
49. Colbert LE, El MB, Lynn EJ, Bronk J, Karpinets TV, Wu X, Chapman BV, Sims TT, Lin D, Kouzy R, Sammouri J, Biegert G, Delgado Medrano AY, Olvera A, Sastry KJ, Eifel PJ, Jhingran A, Lin L, Ramondetta LM, Futreal AP, Jazaeri AA, Schmeler KM, Yue J, Mitra A, Yoshida-Court K, Wargo JA, Solley TN, Hegde V, Nookala SS, Yanamandra AV, Dorta-Estremera S, Mathew G, Kavukuntla R, Papso C, Ahmed-Kaddar M, Kim M, Zhang J, Reuben A, Holliday EB, Minsky BD, Koong AC, Koay EJ, Das P, Taniguchi CM, Klopp A. Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16(+) Cancers. Cancer Immunol Res 10(2):259-271, 2022. e-Pub 2022. PMID: 35045973.
50. Corrigan KL, Kry S, Howell RM, Kouzy R, Jaoude JA, Patel RR, Jhingran A, Taniguchi C, Koong AC, McAleer MF, Nitsch P, Rodel C, Fokas E, Minsky BD, Das P, Fuller CD, Ludmir EB. The radiotherapy quality assurance gap among phase III cancer clinical trials. Radiother Oncol 166:51-57, 2022. e-Pub 2022. PMID: 34838891.
51. Abi Jaoude J, Thunshelle CP, Kouzy R, Nguyen ND, Lin D, Prakash L, Bumanlag IM, Noticewala SS, Niedzielski JS, Beddar S, Ludmir EB, Holliday EB, Das P, Minsky BD, Herman JM, Katz M, Koong AC, Koay EJ, Taniguchi CM. Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. Adv Radiat Oncol 6(6):100763, 2021. e-Pub 2021. PMID: 34934858.
52. Abi Jaoude J, Kouzy R, Rooney M, Thompson P, Patel R, Turner MC, Ghabach M, Fuller CD, Minsky BD, Taniguchi CM, Ludmir EB. Impact factor and citation metrics in phase III cancer trials. Oncotarget 12(18):1780-1786, 2021. e-Pub 2021. PMID: 34504650.
53. Abi Jaoude J, Kouzy R, Ghabach M, Patel R, Pasalic D, Ghossain E, Miller AB, Lin TA, Verma V, Fuller CD, Subbiah V, Minsky BD, Ludmir EB, Taniguchi CM. Food and Drug Administration approvals in phase 3 Cancer clinical trials. BMC Cancer 21(1):695, 2021. e-Pub 2021. PMID: 34118915.
54. Lin D, Moningi S, Abi Jaoude J, Singh BS, Cazacu IM, Kouzy R, Nogueras Gonzalez GM, Angsuwatcharakon P, Herman JM, Bhutani MS, Taniguchi CM. Development of an Objective Scoring System for Endoscopic Assessment of Radiation-Induced Upper Gastrointestinal Toxicity. Cancers (Basel) 13(9), 2021. e-Pub 2021. PMID: 33946696.
55. Moningi S, Abi Jaoude J, Kouzy R, Lin D, Nguyen ND, Garcia Garcia CJ, Phan JL, Avila S, Smani D, Cazacu IM, Singh BS, Smith GL, Holliday EB, Koay EJ, Das P, Bhutani MS, Herman JM, Minsky BD, Koong AC, Taniguchi CM. Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer. Adv Radiat Oncol 6(2):100621, 2021. e-Pub 2021. PMID: 33912734.
56. El Alam MB, Sims TT, Kouzy R, Biegert GWG, Jaoude JABI, Karpinets TV, Yoshida-Court K, Wu X, Delgado-Medrano AY, Mezzari MP, Ajami NJ, Solley T, Ahmed-Kaddar M, Lin LL, Ramondetta L, Jazaeri A, Jhingran A, Eifel PJ, Schmeler KM, Wargo J, Klopp AH, Colbert LE. A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancers. PLoS One 16(3):e0247905, 2021. e-Pub 2021. PMID: 33662003.
57. Kouzy R, Abi Jaoude J, Lin D, El Alam MB, Minsky BD, Koay EJ, Das P, Holliday EB, Klopp AH, Colbert LE, Taniguchi CM. Patient-Reported GI Outcomes in Patients With Anal Cancer Receiving Modern Chemoradiation. JCO Oncol Pract 16(12):e1524-e1531, 2020. e-Pub 2020. PMID: 32609585.
58. Kouzy R, Abi Jaoude J, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, Verma V, Fuller CD, Minsky BD, Rodel C, Taniguchi CM, Ludmir EB. Professional Medical Writer Assistance in Oncology Clinical Trials. Oncologist 25(11):e1812-e1815, 2020. e-Pub 2020. PMID: 32885898.
59. Abi Jaoude J, Kouzy R, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, Pasalic D, Verma V, VanderWalde NA, Smith BD, Smith GL, Fuller CD, Das P, Minsky BD, Rodel C, Fokas E, Jagsi R, Thomas CR, Subbiah IM, Taniguchi CM, Ludmir EB. Performance Status Restriction in Phase III Cancer Clinical Trials. J Natl Compr Canc Netw 18(10):1322-1326, 2020. e-Pub 2020. PMID: 33022640.
60. Kouzy R, Abi Jaoude J, Garcia Garcia CJ, El Alam MB, Taniguchi CM, Ludmir EB. Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic. JAMA Netw Open 3(7):e2015100, 2020. e-Pub 2020. PMID: 32658285.
61. Kouzy R, Abi Jaoude J, Yue J, Maldonado JA, Taniguchi CM, Ludmir EB, Colbert LE. Applying to Radiation Oncology Amid a Pandemic. Adv Radiat Oncol 5(4):777-779, 2020. e-Pub 2020. PMID: 32775792.
62. Kouzy R, Abi Jaoude J, Kraitem A, El Alam MB, Karam B, Adib E, Zarka J, Traboulsi C, Akl EW, Baddour K. Coronavirus Goes Viral: Quantifying the COVID-19 Misinformation Epidemic on Twitter. Cureus 12(3):e7255, 2020. e-Pub 2020. PMID: 32292669.
63. Kouzy R, Alawieh R, Sukhon F, Temraz S. A Case of Typical Hemolytic Uremic Syndrome in an Adult. Cureus 10(9):e3289, 2018. e-Pub 2018. PMID: 30443459.

Review Articles

1. Patel M, Favorito FM, Patel RK, Kouzy R, Du K, Ynoe de Moraes F, Bitterman DS, Katz L. AI literacy among healthcare professionals and students in the Americas. Lancet Reg Health Am 60:101489, 2026. e-Pub 2026. PMID: 42110579.
2. Ni HM, Kouzy R, Sabbagh A, Rooney MK, Feng J, Castillo SP, Gadoue SM, El Kouzi Z, Hoffman K, Yuan Y, Madabhushi A, Mohamad O. The state of the art in artificial intelligence and digital pathology in prostate cancer. Nat Rev Urol 23(1):13-28, 2026. e-Pub 2026. PMID: 40760335.
3. Kouzy R, Cha EE, Rosen A, Bitterman DS. Review of Large Language Models for Patient and Caregiver Support in Cancer Care Delivery. JCO Clin Cancer Inform 9:e2500044, 2025. e-Pub 2025. PMID: 41213099.
4. Rooney MK, El Kouzi Z, Kouzy R, Mohamad O, Hoffman KE. Debate 1: High-Risk Localized Prostate Cancer: Why Combination Hormone Therapy and Radiotherapy is the Optimal Treatment Strategy for Most Men. Semin Radiat Oncol 35(3):393-401, 2025. e-Pub 2025. PMID: 40516974.
5. Corrigan KL, Rooney MK, Kouzy R, Manzar G, Thomas CR Jr, Ludmir EB. Selection and Prejudice: Addressing Clinical Trial Disparities With a Review of Current Shortcomings and Future Directions. Semin Radiat Oncol 33(4):367-373, 2023. e-Pub 2023. PMID: 37684066.
6. Abi Jaoude J, Kouzy R, Nguyen ND, Lin D, Noticewala SS, Ludmir EB, Taniguchi CM. Radiation therapy for patients with locally advanced pancreatic cancer: Evolving techniques and treatment strategies. Curr Probl Cancer 44(6):100607, 2020. e-Pub 2020. PMID: 32471736.
7. Kouzy R, Abi Jaoude J, Lin D, Nguyen ND, El Alam MB, Ludmir EB, Taniguchi CM. Patient-Reported Outcome Measures in Pancreatic Cancer Receiving Radiotherapy. Cancers (Basel) 12(9), 2020. e-Pub 2020. PMID: 32887363.
8. Lin D, Kouzy R, Abi Jaoude J, Noticewala SS, Delgado Medrano AY, Klopp AH, Taniguchi CM, Colbert LE. Microbiome factors in HPV-driven carcinogenesis and cancers. PLoS Pathog 16(6):e1008524, 2020. e-Pub 2020. PMID: 32497113.

Other Articles

1. Nalin AP, Msaouel P, Grippin AJ, Kouzy R, Abi Jaoude J, Lin TA, Miller AM, Meimoun NS, Ludmir EB, Sherry AD Control arm overperformance in phase 3 oncology clinical trials. Cancer 132(4):e70306, 2026. PMID: 41653086.
2. Brown G, Msaouel P, Miller AM, Kouzy R, Lin TA, Abi Jaoude J, Ludmir EB, Sherry AD Patient, Physician, and Assessor Blinding in Phase III Randomized Trials in Oncology: A Meta-Epidemiological Analysis. Cancer Med 14(15):e71097, 2025. PMID: 40879280.
3. Sherry AD, Miller AM, Parlapalli JP, Kupferman GS, Beck EJ, McDonald J, Kouzy R, Abi Jaoude J, Lin TA, Sanford NN, Chino F, Gyawali B, Booth C, Msaouel P, Ludmir EB Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials: A Meta-Epidemiological Analysis. JAMA Oncol 11(7):718-724, 2025. PMID: 40451185.
4. Mohamad O, Mose L, Ahmadsei M, Kouzy R, Zamboglou C, Nicosia L, Alongi F, Zilli T, Arcangeli S, Marvaso G, Jereczek-Fossa BA, Guckenberger M, Aebersold DM, Shelan M Salvage Radiotherapy Following Nonradiotherapy Ablative Techniques for Primary Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus 11(4):625-637, 2025. PMID: 40221373.

Editorials

1. Kouzy R, Bitterman DS. Improving Patient Engagement: Is There a Role for Large Language Models?. Int J Radiat Oncol Biol Phys 120(3):639-641, 2024. PMID: 39326949.
2. Sherry AD, Msaouel P, Kouzy R, Abi Jaoude J, Lin TA, Taniguchi CM, Fuller CD, Minsky B, Ludmir EB. Lost in the plot: missing visual elements in Kaplan-Meier plots of phase III oncology trials. Oncologist 29(7):547-550, 2024. PMID: 38824414.

Letters to the Editor

1. Kouzy R, Klopp AH. In response to Daungsupawong and Wiwanitkit. Brachytherapy 25: 706, 2026.
2. Kouzy R, Ludmir EB, Hoffman KE, Jhingran A, Kuban DA. In Reply to Akhtar et al. Pract Radiat Oncol 14: 466-467, 2024.
3. Abi Jaoude J, Kouzy R, Minsky BD, Fuller CD, Yuan Y, Do KA, Taniguchi CM, Ludmir EB. Sponsor-involved statistical analyses in Phase III cancer clinical trials. Int J Cancer 147: 3579-3581, 2020.
4. Abi Jaoude J, Kouzy R, El Alam MB, Subbiah V, Taniguchi CM, Ludmir EB, Lin TA. Exclusion of Older Adults in COVID-19 Clinical Trials. Mayo Clin Proc 95: 2293-2294, 2020.
5. Colbert LE, Kouzy R, Abi Jaoude J, Ludmir EB, Taniguchi CM. Cancer Research after COVID-19: Where Do We Go from Here?. Cancer Cell 37: 637-638, 2020.